StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Needham Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
July 17, 2025 7:11 AM
Needham analyst Gil Blum reiterated a Buy rating and $50.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst commented: "Sarepta ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)
July 21, 2025 6:55 AM
BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
July 21, 2025 6:03 AM
Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty'
July 18, 2025 2:19 PM
Sarepta Therapeutics (SRPT) PT Lowered to $20 at BofA Securities, 'Safety reports could limit uptake of SRPT’s gene therapies'
July 18, 2025 9:42 AM
Morgan Stanley Reiterates Equalweight Rating on Sarepta Therapeutics (SRPT)
July 18, 2025 9:33 AM
Goldman Sachs Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
July 18, 2025 8:59 AM
William Blair on Sarepta Therapeutics (SRPT): 'we continue to view the stock’s near-term upside potential as limited'
July 18, 2025 8:58 AM
Leerink Partners Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
July 18, 2025 8:55 AM
Sarepta Therapeutics (SRPT) PT Raised to $28 at TD Cowen
July 18, 2025 5:44 AM
